image

The best stocks to buy since 1993

Latest issue now available

EKF Diagnostics

March 2014

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • EKF
  • Price:
  • 37p
EKF has put out solid full year results with H2 showing a 13% increase in sales over H1. Overall, full year sales were £31.8m, up 22% whilst adjusted ebitda was up 51% to £4.8m. The main boost to the results came from an unexpected revival in sales of Biosen instruments (sales +75% to £6.5m). Demand had been expected to peter out but there has been a revival from diabetes clinics in Russia, Middle East and China. There was also higher than expected sales for the second year running of BHB, an enzymatic assay used on clinical chemistry analysers  (+8% to £3.1m) where a competitor failed to regain its lost ground. Both are high margin areas but their revivals are somewhat unexpected.    In terms of the new bits, QuoLab/ Quo ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

LIMITED PERIOD OFFER

SUBSCRIBE TODAY AND SAVE £40 WITH OFFER CODE 40OFFSCSW

To access our archive of articles and to receive current issues you need to subscribe